Literature DB >> 28197314

Combretastatin A4-β-Galactosyl Conjugates for Ovarian Cancer Prodrug Monotherapy.

Tomohiro Doura1, Kazuaki Takahashi1, Yasumitsu Ogra1, Noriyuki Suzuki1.   

Abstract

Chemotherapy for ovarian cancer often causes severe side effects. As candidates for combretastatin A4 (CA4) prodrug for ovarian cancer prodrug monotherapy (PMT), we designed and synthesized two β-galactose-conjugated CA4s (CA4-βGals), CA4-βGal-1 and CA4-βGal-2. CA4 was liberated from CA4-βGals by β-galactosidase, an enzyme more strongly expressed in ovarian cancer cells than normal cells. CA4-βGal-2, which has a self-immolative benzyl linker between CA4 and the β-galactose moiety, was more cytotoxic to ovarian cancer cell lines than CA4-βGal-1 without a linker. Therefore, CA4-βGal-2 can serve as a platform for the design and manufacture of prodrugs for ovarian cancer PMT.

Entities:  

Keywords:  Antitumor agent; combretastatin A4; ovarian cancer; prodrug monotherapy; tubulin polymerization inhibitor; β-galactosidase

Year:  2017        PMID： 28197314      PMCID： PMC5304305          DOI： 10.1021/acsmedchemlett.6b00427

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


  17 in total

1.  Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

Authors:  Deborah K Armstrong; Brian Bundy; Lari Wenzel; Helen Q Huang; Rebecca Baergen; Shashikant Lele; Larry J Copeland; Joan L Walker; Robert A Burger
Journal:  N Engl J Med       Date:  2006-01-05       Impact factor: 91.245

Review 2.  Cancer of the ovary.

Authors:  Stephen A Cannistra
Journal:  N Engl J Med       Date:  2004-12-09       Impact factor: 91.245

3.  Synthesis and antitumor-evaluation of cyclopropyl-containing combretastatin analogs.

Authors:  Rita Fürst; István Zupkó; Agnes Berényi; Gerhard F Ecker; Uwe Rinner
Journal:  Bioorg Med Chem Lett       Date:  2009-10-20       Impact factor: 2.823

4.  Lipophilicity in drug discovery.

Authors:  Michael J Waring
Journal:  Expert Opin Drug Discov       Date:  2010-03       Impact factor: 6.098

5.  Beta-D-glycosylamidines: potent, selective, and easily accessible 1-glycosidase inhibitors.

Authors:  W Guo; J Hiratake; K Ogawa; M Yamamoto; S J Ma; K Sakata
Journal:  Bioorg Med Chem Lett       Date:  2001-02-26       Impact factor: 2.823

6.  Activity of lysosomal exoglycosidases in human gliomas.

Authors:  P Wielgat; U Walczuk; S Szajda; M Bień; L Zimnoch; Z Mariak; K Zwierz
Journal:  J Neurooncol       Date:  2006-05-19       Impact factor: 4.130

7.  Synthesis and biological evaluation of novel prodrugs of anthracyclines for selective activation by the tumor-associated protease plasmin.

Authors:  F M de Groot; A C de Bart; J H Verheijen; H W Scheeren
Journal:  J Med Chem       Date:  1999-12-16       Impact factor: 7.446

8.  Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: a structure-activity study.

Authors:  C M Lin; S B Singh; P S Chu; R O Dempcy; J M Schmidt; G R Pettit; E Hamel
Journal:  Mol Pharmacol       Date:  1988-08       Impact factor: 4.436

9.  Enzyme activity in invasive tumors of human breast and colon.

Authors:  H B Bosmann; T C Hall
Journal:  Proc Natl Acad Sci U S A       Date:  1974-05       Impact factor: 11.205

10.  Plasmin-activated prodrugs for cancer chemotherapy. 2. Synthesis and biological activity of peptidyl derivatives of doxorubicin.

Authors:  P K Chakravarty; P L Carl; M J Weber; J A Katzenellenbogen
Journal:  J Med Chem       Date:  1983-05       Impact factor: 7.446
View more
  5 in total

1.  Deciphering the origins of molecular toxicity of combretastatin A4 and its glycoconjugates: interactions with major drug transporters and their safety profiles in vitro and in vivo.

Authors:  Zhenhua Huang; Gentao Li; Xue Wang; Hu Xu; Youcai Zhang; Qingzhi Gao
Journal:  Medchemcomm       Date:  2017-06-12       Impact factor: 3.597

Review 2.  Recent advances in combretastatin based derivatives and prodrugs as antimitotic agents.

Authors:  Zaki S Seddigi; M Shaheer Malik; A Prasanth Saraswati; Saleh A Ahmed; Ahmed O Babalghith; Hawazen A Lamfon; Ahmed Kamal
Journal:  Medchemcomm       Date:  2017-07-04       Impact factor: 3.597

Review 3.  Nanotechnology for angiogenesis: opportunities and challenges.

Authors:  Saeid Kargozar; Francesco Baino; Sepideh Hamzehlou; Michael R Hamblin; Masoud Mozafari
Journal:  Chem Soc Rev       Date:  2020-06-15       Impact factor: 54.564

Review 4.  More Than Resveratrol: New Insights into Stilbene-Based Compounds.

Authors:  Paulina Pecyna; Joanna Wargula; Marek Murias; Malgorzata Kucinska
Journal:  Biomolecules       Date:  2020-07-27

5.  An Unrevealed Molecular Function of Corannulene Buckybowl Glycoconjugates in Selective Tumor Annihilation by Targeting the Cancer-Specific Warburg Effect.

Authors:  Shengnan Liu; Ziru Sun; Min Liang; Weijie Song; Ru Zhang; Yunli Shi; Yujun Cui; Qingzhi Gao
Journal:  Adv Sci (Weinh)       Date:  2022-03-07       Impact factor: 16.806
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.